DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), GABA receptor agonists(Gamma-aminobutyric acid (GABA) receptors agonists), Proton pump inhibitors

Therapeutic Areas

Immune System DiseasesEndocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 1

Inactive Indication-

Originator Organization

LeviCure Ltd.

Active Organization

University of Uppsala

LeviCure Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

100 Clinical Results associated with T1DM triple-therapy (Levicure)

100 Translational Medicine associated with T1DM triple-therapy (Levicure)

100 Patents (Medical) associated with T1DM triple-therapy (Levicure)

Literatures (Medical) associated with T1DM triple-therapy (Levicure)

01 Jan 2023·Frontiers in endocrinology

Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes.

Article

Author: Schiöth, Helgi B ; Levit, Shmuel ; Koshelev, Daniil ; Kosheleva, Liudmila ; Lagunas-Rangel, Francisco Alejandro ; Rabinovitch, Alexander ; Gavra, Tali

IntroductionThe purpose of this retrospective clinic chart review study was to determine the potential of a combination therapy (CT) consisting of γ-aminobutyric acid (GABA), a dipeptidyl peptidase-4 inhibitor (DPP-4i), and a proton pump inhibitor (PPI) to improve glycemic control as an adjunct to insulin therapy in patients with type 1 diabetes (T1D).Research design and methodsNineteen patients with T1D on insulin therapy were treated with additional CT in oral form. Fasting blood glucose (FBG), HbA1c, insulin dose-adjusted HbA1c (IDA-A1c), daily insulin dose, insulin/weight ratio (IWR), and fasting plasma C-peptide were measured after 26-42 weeks of treatments.ResultsFBG, HbA1c, IDA-A1c, insulin dose and IWR were all significantly decreased while plasma C-peptide was significantly increased by the CT. Treatment outcomes were further analyzed by separation of the 19 patients into two groups. One group started on the CT within 12 months of insulin treatment (early therapy, 10 patients) and another group started on this therapy only after 12 months of insulin treatment (late therapy, 9 patients). FBG, IDA-A1c, insulin dose, and IWR decreased significantly in both the early and late CT groups, however to a better extent in the early therapy group. Moreover, plasma C-peptide increased significantly only in the early therapy group, and 7 of the 10 patients in this group were able to discontinue insulin treatment while maintaining good glycemic control to study end compared with none of the 9 patients in the late therapy group.ConclusionThese results support the concept that the combination of GABA, a DPP-4i and a PPI as an adjunct to insulin therapy improves glycemic control in patients with T1D, and that the insulin dose required for glycemic control can be reduced or even eliminated in some patients receiving this novel therapy.

100 Deals associated with T1DM triple-therapy (Levicure)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Phase 2	Israel	LeviCure Ltd.	24 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Front Endocrinol (Lausanne) Manual	Clinical	Diabetes Mellitus, Type 1 plasma C-peptide	19	Combination Therapy (GABA + DPP-4i + PPI), started within 12 months of insulin treatment (early therapy)	(ahbqvfdrpn) = Increased significantly only in the early therapy group. xlytpmmasd (tpoxbyveps ) View more	Positive	24 May 2023
				Combination Therapy (GABA + DPP-4i + PPI), started after 12 months of insulin treatment (late therapy)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

T1DM triple-therapy (Levicure)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation